论文部分内容阅读
目的探讨依达拉奉联合尤瑞克林治疗急性脑梗死的效果。方法随机选取2013年10月至2015年10月均经脑部CT或MRI检查确诊的急性脑梗死患者70例,随机分为联合组和单药组,每组35例。联合组行依达拉奉与尤瑞克林治疗,单药组给予依达拉奉治疗,比较两组治疗效果。结果联合组总有效率(94.29%)高于单药组(74.29%),差异有统计学意义(P<0.05)。治疗后3个月,两组NIHSS评分均降低,而ADL评分均升高,但联合组程度均更为显著,差异有统计学意义(P<0.05)。结论依达拉奉联合尤瑞克林对急性脑梗死安全有效,值得临床推广应用。
Objective To investigate the effect of edaravone combined with norepinephrine in the treatment of acute cerebral infarction. Methods Seventy patients with acute cerebral infarction diagnosed by brain CT or MRI from October 2013 to October 2015 were randomly divided into the combined group and the single drug group, with 35 cases in each group. Combination group edaravone and uricin treatment, single-drug group was treated with edaravone, the treatment effect was compared between the two groups. Results The total effective rate (94.29%) in the combined group was higher than that in the single drug group (74.29%), the difference was statistically significant (P <0.05). Three months after treatment, the NIHSS scores decreased and the ADL scores increased in both groups, but the joint group was more significant (P <0.05). Conclusion Edaravone combined with norepinephrine is safe and effective for acute cerebral infarction and is worthy of clinical application.